TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02875379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurements
Description: Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Study: NCT03969160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Imaginal exposure to mental imagery of phobic and neutral stimuli
Study: NCT04768283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional balance and resistance training - 1
Description: Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional balance and resistance training - 2
Description: Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction.
Study: NCT03592680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
Study: NCT02875379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurements
Description: Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurements
Description: Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurements
Description: Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Study: NCT01826656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: Patients from both groups will follow the extraction of an hopeless tooth

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tooth extraction
Description: Patients from both groups will follow the extraction of an hopeless tooth

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CBCT scan
Description: A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)

Intervention type: RADIATION
Group type: OTHER
Intervention: CBCT scan
Description: A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scan
Description: DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
Study: NCT03182972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: Pre-post intervention
Study: NCT01826656

Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scan
Description: DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Panoramic radiograph
Description: As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis

Intervention type: RADIATION
Group type: OTHER
Intervention: Panoramic radiograph
Description: As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
Study: NCT02607618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclaprim
Description: Experimental treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator
Study: NCT00655538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 600mg po daily for 36 weeks
Study: NCT04367831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Prophylactic Dose
Description: Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Infusion
Description: Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin SC
Description: Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin/Lovenox Intermediate Dose
Description: If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
Study: NCT03351647

Intervention type: BIOLOGICAL
Intervention: Evaluation of biological predictive factors of clinical response to ustekinumab
Description: The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
Study: NCT02695251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low AGE meal
Description: Patients will receive a low AGE (eggs) meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High AGE meal
Description: Patients will receive a high (mixed nuggets) AGE (eggs) meal
Study: NCT01762800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol placebo
Description: Placebo, Twice daily (morning and evening)
Study: NCT00820742

Intervention type: DRUG
Intervention: Macugen
Description: Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
Study: NCT01398566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SuperBetter play
Description: average 10 min of game play per day for 6 week period
Study: NCT00838201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
Study: NCT04348513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3 solution for injection
Description: For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as with T3 solution for injection.
Study: NCT00915863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth-II-type reconstruction
Description: surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Roux-en-Y type reconstruction
Description: surgical procedure
Study: NCT00410761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: once daily oral tablet
Study: NCT01762800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 18mcg
Description: Active, 18mcg, Once daily(morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide placebo
Description: Placebo, Once daily(morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
Description: Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
Study: NCT01054482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy
Description: Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative concurrent chemoradiation therapy
Description: Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
Study: NCT03004911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFibro (Mobile application)
Description: ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paper booklet
Description: A 64-page booklet with content similar to the mobile application
Study: NCT03128242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin (24IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intranasal administration of placebo (24IU)
Study: NCT02912715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel releasing angioplasty balloon
Description: Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
Study: NCT04449627

Intervention type: OTHER
Intervention: Feeling Good Digital App
Description: Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
Study: NCT04355403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalo Gyn gel in prefilled applicators
Description: One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
Study: NCT02485132

Intervention type: OTHER
Intervention: Observational
Description: Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
Study: NCT02103491

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt administration
Description: Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Study: NCT01061359

Intervention type: DRUG
Intervention: Epirubicin: Observational Study
Description: Observational: Chemotherapy
Study: NCT05425329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I3.1
Description: Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Capsule containing maltodextrin.
Study: NCT04450940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACV survey
Study: NCT03653793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Health Product: LivRelief Varicose Veins Cream
Description: This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
Study: NCT03827486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (exercise)
Description: Exercise program according to the standard of care
Study: NCT04450940

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo survey
Study: NCT03038126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCHT
Description: Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard clinical care
Study: NCT03847935

Intervention type: PROCEDURE
Intervention: surgery
Description: A1 pulley release of finger

Intervention type: PROCEDURE
Intervention: corticosteroid injections
Description: corticosteroid injection to A1 pulley

Intervention type: PROCEDURE
Intervention: corticosteroid injections
Description: corticosteroid injection to A1 pulley

Intervention type: PROCEDURE
Intervention: corticosteroid injections
Description: corticosteroid injection to A1 pulley

Intervention type: OTHER
Intervention: Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,

Intervention type: OTHER
Intervention: Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,

Intervention type: OTHER
Intervention: Modality Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis

Intervention type: OTHER
Intervention: Modality Hand Therapy
Description: orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
Study: NCT04424667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: donor milk
Description: pasteurized donor milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: donor milk
Description: pasteurized donor milk
Study: NCT06271044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With radioiodine treatment
Description: Postoperative radioiodine not given

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With postoperative radioiodine treatment
Description: Postoperative radioiodine given
Study: NCT01597635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 GSK2586881
Description: Low dose GSK2586881 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 GSK2586881
Description: Medium dose GSK2586881 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 GSK2586881
Description: Medium-High dose GSK2586881 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 GSK2586881
Description: Medium-High dose GSK2586881 administered intravenously
Study: NCT03827486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domicilary exercise program
Description: Domicilary exercise program according to protocol (evidence based medicine)
Study: NCT04387201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
Study: NCT01597635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4 GSK2586881
Description: High dose GSK2586881 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Administered intravenously to match intervention
Study: NCT03890588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD enhanced clinical decision support
Description: The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
Study: NCT01186302

Intervention type: OTHER
Group type: OTHER
Intervention: Type of provider
Description: Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.

Intervention type: OTHER
Group type: OTHER
Intervention: Type of provider
Description: Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
Study: NCT04403451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: True North
Description: Love Notes, Financial Stability, Jobs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: True North
Description: Love Notes, Financial Stability, Jobs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: True North
Description: Love Notes, Financial Stability, Jobs
Study: NCT01395901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Single dose Ondansetron IV:~* 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg;~* 13 years to less than 17 years dose: 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Palonosetron
Study: NCT02068794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04300478

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: REx Condition First
Description: REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: REx Condition First
Description: REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sedentary Control Condition First
Description: Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.